StemCells soars 600% on reverse merger with Israel ’ s Microbot Medical
Shares in StemCells (NSDQ:STEM) initially soared some 600% this week after the company initiated a reverse merger with Microbot Medical, after the failure of a Phase II trial of StemCells’ spinal cord injury treatment. The merger also saw the resignation of CEO Ian Massey, CFO Gregory Schiffman and a trio of board members, as the team led by Microbot chairman & CEO Harel Gadot prepares to take over. Kenneth Stratton was tapped to serve as interim president, effective August 15. The reverse merger sent STEM shares up 602.7% to a $2.60 close August 16, the day the deal was announced; t...
Source: Mass Device - August 19, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Robotics Microbot Medical StemCells Source Type: news

Cianna nets FDA OK for radar system
Brachytherapy firm Cianna Medical has received an additional 510(k) clearance...Read more on AuntMinnie.comRelated Reading: Cianna highlights SAVI Scout results at SBI Cianna advances 2 SAVI Scout studies Cianna nets FDA OK for SAVI Scout Cianna promotes SAVI results at ASCO BCS Cianna touts breast brachy results at ASBrS show (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 18, 2016 Category: Radiology Source Type: news

High-dose radiation therapy as effective as surgery for aggressive prostate cancer
This study was the first of its kind to directly compare outcomes between radiation-based treatments and surgery for patients with cancers that are Gleason score nine or 10 (the highest score possible, which represents the most aggressive form of cancer). BACKGROUND Prostate cancer is the most common form of cancer among men in the United States, with nearly 180,000 new cases expected to be diagnosed in 2016 alone. Therefore, identifying the optimal treatment strategies for this malignancy is particularly important. In the past oncologists suggested that surgery and radiation-based treatments offer equivalent outcomes. How...
Source: UCLA Newsroom: Health Sciences - August 6, 2016 Category: Universities & Medical Training Source Type: news

Medical News Today: Internal radiation therapy: Better response in metastatic colorectal cancer patients
New analysis shows patients with metastatic colorectal cancer treated with radiation therapy show better response than those receiving chemotherapy alone. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2016 Category: Consumer Health News Tags: Radiology / Nuclear Medicine Source Type: news

C4 touts MRI-guided prostate brachytherapy study
Image-guided technology developer C4 Imaging said that a recent research study...Read more on AuntMinnie.comRelated Reading: C4 raises $1.3M for multimodality marker C4 Imaging nets 510(k) clearance for MRI marker (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2016 Category: Radiology Source Type: news

Brachytherapy pioneer Haakon Ragde, M.D., chosen as ASTRO 2016 Honorary Member
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) has selected Haakon Ragde, M.D., as its 2016 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2016 Category: Global & Universal Source Type: news

IsoRay touts brachytherapy brain cancer trial
IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site. The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after tumor removal. IsoRay called the technique the “GammaTile” approach, but clarified that it is not commercially available. A total of 95% of the treated tumors showed no radiographic evidence of regrowth of the tumor at ...
Source: Mass Device - June 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neurological Radiosurgery IsoRay Source Type: news

IsoRay touts brain brachytherapy study results
Medical isotope developer IsoRay Medical is highlighting findings from a prospective...Read more on AuntMinnie.comRelated Reading: IsoRay revenue edges higher, but net loss grows IsoRay taps new VP of sales, marketing IsoRay posts mixed Q2 results IsoRay reports flat sales IsoRay picks new distributor for Australia, New Zealand (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 21, 2016 Category: Radiology Source Type: news

Recurrent DES Failure: Try Radiation? (CME/CE)
(MedPage Today) -- Brachytherapy associated with 'reasonable' short-term outcomes in study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 21, 2016 Category: Cardiology Source Type: news

Elekta inks U.S. brachytherapy distro deal with Kobold Medical.
Elekta (STO:EKTA B) said yesterday it inked a distribution deal with Kobold Medical to distribute its brachytherapy applicators within the U.S. Through the deal, Elekta will market and distribute 4 kobold applicators, as well as its prostate template, the company said. “We are pleased to offer our brachytherapy users in the United States these high quality products from Kobold. Adding these solutions to our brachytherapy portfolio will help us better serve the needs of clinical providers,” Elekta North America exec veep Bill Yaeger said in a press release. Included in the distribution deal is Kobold Medica...
Source: Mass Device - June 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Distribution Radiosurgery Elekta AB Kobold Medical Source Type: news

Theragenics signs on Japanese distributor
Brachytherapy seed manufacturer Theragenics has signed on Nihon Medi-Physics...Read more on AuntMinnie.comRelated Reading: Theragenics to distribute ART's AccuBoost Theragenics signs brachytherapy services deal with Oncura Eckert & Ziegler withdraws Theragenics bid Eckert & Ziegler pursues bid for Theragenics Theragenics inks MedAssets distribution deal (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 7, 2016 Category: Radiology Source Type: news

Imaging takes leading role in penis transplant
When Thomas Manning underwent one of the world's first successful penis transplant...Read more on AuntMinnie.comRelated Reading: Drug aids sexual function of prostate cancer patients after RT Robotic prostate brachytherapy technique avoids penile damage Don't amputate! Treat penile cancer with radiation therapy Point/counterpoint: Prostate cancer researchers battle over treatment options MRI helps assess need for surgery in penile fracture (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 6, 2016 Category: Radiology Source Type: news

Elekta wins Swedish hospital supply deal
Elekta (STO:EKTA B) said today it won a supply agreement with the Stockholm County Council to supply equipment to its flagship New Karolinska Solna hospital. The company said it expects the deal to be formally signed during its the 1st quarter of fiscal year 2016/2017, with the bulk of installations scheduled for April 2017. “As a Swedish corporation headquartered in Stockholm, and as a world leader in cancer care, we are delighted to be awarded this prestigious tender. We are fully committed to investing in research and innovation and in providing our state-of-the-art technology in collaboration with NKS, in or...
Source: Mass Device - May 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Elekta AB Source Type: news

Elekta Wins Public Tender to Deliver Advanced Cancer Care Solutions to New Karolinska Solna (NKS)
STOCKHOLM--(Healthcare Sales & Marketing Network)--Stockholm County Council (Sweden), announced today that Elekta has been awarded the public tender to exclusively equip the Radiation Therapy Department of its new, flagship hospital, the New Karolinska Sol... Devices, Oncology, NeurosurgeryElekta, radiation therapy, radiosurgery, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 25, 2016 Category: Pharmaceuticals Source Type: news

Humediq wins $9.9m in spat with Elekta
Elekta (STO:EKTA B) said today that an arbitration tribunal in London this week found in favor of Humediq to the tune of $9.9 million (EU €8.9 million) in a spat with 2 Elekta subsidiaries over exclusive supply agreements. The dispute is over an agreement Elekta entered into in 2011 in which it became the exclusive supplier of Humediq’s Identify system patient identification and validation system. Elekta said it decided to discontinue marketing and sales of the Identify system in late 2014, due to “the product’s commercial viability,” according to a press release. The tribunal fo...
Source: Mass Device - May 24, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Legal News Patient Monitoring Elekta AB Humediq Source Type: news

MD Anderson Cancer Center to Acquire Elekta Linear Accelerators and Other Radiotherapy Solutions
HOUSTON, Texas, April 26, 2016 -- (Healthcare Sales & Marketing Network) -- The University of Texas MD Anderson Cancer Center has signed a deal with Elekta (EKTA-B.ST) to acquire Elekta Infinity™ linear accelerators, brachytherapy afterloaders as well as ... Devices, OncologyElekta, Infinity, linear accelerator, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 26, 2016 Category: Pharmaceuticals Source Type: news

IsoRay spikes GliaSite radiation therapy device
IsoRay (NYSE:ISR) said yesterday that it’s spiking its GliaSite radiation therapy system for treating brain cancers, after achieving only modest sales since the FDA cleared the device in 2011. Richland, Wash.-based IsoRay said it’s cancelling its deals with Dr. Reddy’s Laboratories (NYSE:RDY), Hologic (NSDQ:HOLX) and Karlheinz Goehl-Medizintechnik Goehl concerning GliaSite. “The GliaSite product has resulted in only marginal sales, but it was the first delivery system available to the company to deliver brachytherapy radiation in the treatment of brain cancer. Management believes...
Source: Mass Device - April 13, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Oncology Radiosurgery IsoRay Source Type: news

Brachytherapy (Seed Implants) for Prostate Cancer
It is important to understand the potential side effects that may result from brachytherapy (seed implants) for prostate cancer. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - April 8, 2016 Category: Cancer & Oncology Tags: health Source Type: news

Cianna highlights SAVI Scout results at SBI
At this week's Society of Breast Imaging (SBI) meeting in Austin, TX, brachytherapy...Read more on AuntMinnie.comRelated Reading: Cianna advances 2 SAVI Scout studies Cianna nets FDA OK for SAVI Scout Cianna promotes SAVI results at ASCO BCS Cianna touts breast brachy results at ASBrS show Cianna touts breast brachytherapy results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 7, 2016 Category: Radiology Source Type: news

FDA releases February 2016 510(k) clearances
February 2016 510(k) Clearances 510(k) summaries or 510(k) statements for final decisions rendered during the period February 2016. TOTAL 510(k)s THIS PERIOD 224 TOTAL WITH SUMMARIES 213 TOTAL WITH STATEMENTS 11 February 2016 510(k) Clearances 510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL DECISIONS RENDERED DURING THE PERIOD February 2016 DEVICE: ANI Monitor MDOLORIS MEDICAL SYSTEMS SAS 510(k) NO: K142969(Traditional) ATTN: MATHILDE COLLET PHONE NO : 011 333 62092081 6, RUE DU PR LAGUESSE SE DECISION MADE: 23-FEB-16 LILLE FR 59037 510(k) SUMMARY AVAILABLE FROM FDA DEVICE: DBSWIN and VistaEasy Imaging Software Durr Dental...
Source: Mass Device - April 5, 2016 Category: Medical Equipment Authors: MassDevice Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Elekta inks $100m deal Down Under
Elekta (STO:EKTA B) said yesterday it inked an 8-year strategic partnership with Australian radiotherapy provider GenesisCare for more than $100m. The new partnership includes the acquisition of Elekta’s Leksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software and other services, Elekta said. “We are proud to partner alongside GenesisCare and support their exciting vision. By choosing Elekta, GenesisCare will receive the most advanced and recognized cancer treatment solutions on the market. Both Leksell Gamma Knife and Versa HD are known for their extreme...
Source: Mass Device - April 1, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Elekta AB Source Type: news

Breast Brachytherapy - SAVI Device for...
Learn about the SAVI breast brachytherapy device for reducing recurrence after a lumpectomy via accelerated partial breast irradiation. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 27, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Interstitial Brachytherapy for Early-Stage...
What should I know about nterstitial brachytherapy for breast cancer, and how is it different than whole breast radiation? (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 25, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

The Netherlands' Radiotherapy Group is Country's First to Use Elekta's Esteya Electronic Brachytherapy to Treat Skin Cancer Patients
EDE, Netherlands, March 22, 2016 -- (Healthcare Sales & Marketing Network) -- On March 3, Radiotherapy Group clinicians at Ziekenhuis Gelderse Vallei (Ede, the Netherlands) used their Esteya® electronic brachytherapy system for the first time to treat... Devices, OncologyElekta, Esteya, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2016 Category: Pharmaceuticals Source Type: news

Survival Benefit of SIRT in mCRC UncertainSurvival Benefit of SIRT in mCRC Uncertain
Dr David Kerr looks at a study of selective internal radiation therapy in hepatic metastatic colorectal cancer, but says the lack of survival data puts the clinical utility of SIRT in question. Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 21, 2016 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

An invitation to ESTRO 35
(European Society for Radiotherapy and Oncology (ESTRO)) The ESTRO 35 congress will feature new research results in clinical radiation oncology, radiobiology, physics, technology, patient care, radiation therapy and brachytherapy, presented by top doctors, scientists and radiation therapists from all over the world, working together for the benefit of cancer patients.The congress is expected to attract 5,000 delegates from more than 80 countries. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 26, 2016 Category: Cancer & Oncology Source Type: news

Advanced Medical Isotope hires IR firm Circadian Group
Advaned Medical Isotope Corp said Wednesday it hired medical device, pharma and biotech-focused investor relations firm Circadian Group. Newly-retained Circadian group will focus on presenting AMIC’s past success, current corporate profile and future catalysts to potential international investors. “Circadian Group is an excellent fit for AMIC. Circadian’s expertise in our industry at our stage of development, along with outstanding recommendations from current and past clients contributed to our decision to retain them. We believe that 2016 is going to be a pivotal year for AMIC, and we feel confiden...
Source: Mass Device - January 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Oncology Radiosurgery Advanced Medical Isotope Corp. Source Type: news

IsoRay Appoints Thomas LaVoy as CEO to Take Office on February 15
RICHLAND, Wash., Jan. 14, 2016 -- (Healthcare Sales & Marketing Network) -- IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head... Devices, Oncology, PersonnelIsoRay, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 14, 2016 Category: Pharmaceuticals Source Type: news

Living With Cancer
Seek support in dealing with guilt about lifestyle choices Are you holding on to guilt over what might have caused your cancer? If so, focus on more positive thoughts and behaviors instead. Prostate brachytherapy This form of radiation helps treat prostate cancer. Know how you can prepare and what to expect. Take a moment to [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 18, 2015 Category: Databases & Libraries Source Type: news

AMIC reports progress on RadioGel FDA clearance
Medical isotope developer Advanced Medical Isotope (AMIC) is continuing to...Read more on AuntMinnie.comRelated Reading: AMIC resubmits Y-90 RadioGel to FDA AMIC nets brachytherapy-related patent AMIC looks for European investors AMIC and GSG form strategic alliance AMIC submits RadioGel data to FDA (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 18, 2015 Category: Radiology Source Type: news

Study Oversells HIFU Benefits, Especially in Low-Risk PCaStudy Oversells HIFU Benefits, Especially in Low-Risk PCa
Dr Gerald Chodak disputes the conclusions of a study comparing HIFU therapy with brachytherapy for patients with low or intermediate-risk prostate cancer. Medscape Urology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 23, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Concerns Over Sudden Increase in Radiation for Skin CancerConcerns Over Sudden Increase in Radiation for Skin Cancer
The use of first-line electronic brachytherapy for nonmelanoma skin cancer has risen 20-fold, raising concerns over inappropriate use. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 21, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

My cancer and hysterectomy journey – Julie’s story
The post My cancer and hysterectomy journey – Julie’s story appeared first on Hysterectomy Association. I’m not going to post too long a story – believe me this is just the short version (!) and I hope anyone going through a similar experience will benefit from my tale – and my positive outcome. I was diagnosed in December 2014 with uterine cancer after suddenly starting to bleed heavily in September (hadn’t had a period for about 3 years). Initial diagnosis and MRI imaging were positive and I was led to expect a straightforward op (total abdominal hysterectomy plus ovaries), which would...
Source: The Hysterectomy Association - October 19, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Your Stories brachytherapy uterine cancer Source Type: news

High-Dose-Rate Brachytherapy in Prostate Cancer: What Role?High-Dose-Rate Brachytherapy in Prostate Cancer: What Role?
Dr Gerald Chodak talks about the potential role of this treatment approach, alone or in combination with intensity-modulated radiation therapy, in high-risk prostate cancer. Medscape Urology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 16, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

TCT 2015 Roundup: St. Jude Medical’s new HeartMate PHP pump
St. Jude Medical (NYSE:STJ) said today that its newly acquired HeartMate PHP heart pump met its safety and efficacy endpoints in the Shield I trial used to back its CE Mark approval last summer. The results from Shield I’s 1st 30 patients led to the CE Mark nod in July. Today St. Jude said data from 46 subjects passed the primary safety endpoint of a composite of major adverse events and the primary efficacy endpoint of freedom from hemodynamic compromise during percutaneous coronary intervention. The study results, released today at the annual Transcatheter Cardiovascular Therapeutics conference ...
Source: Mass Device - October 14, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Catheters Clinical Trials Elixir Medical Corp. Micell Technologies Inc. St. Jude Medical Stentys TCT 2015 Tryton Medical Inc. Source Type: news

Salutaris Medical Devices Announces 510(k) Clearance
Salutaris Medical Devices (SalutarisMD) announced that its SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The SMD Sr90-1 RBS is indicated for episcleral brachytherapy of tumors and benign growths, and is intended for use within a manual brachytherapy applicator system. (Source: Medical Design Online News)
Source: Medical Design Online News - September 8, 2015 Category: Medical Equipment Source Type: news

Theragenics to Distribute the AccuBoost(R) Technology for Treatment of Early Stage Breast Cancer
Non-Invasive Brachytherapy Treatment Supplements Breast Conservation Therapy BUFORD, Ga.--(Healthcare Sales & Marketing Network)--Theragenics Corporation®, a medical device company serving the cancer treatment and surgical product markets, has reach... Devices, Oncology, DistributionTheragenics, Advanced Radiation Therapy, AccuBoost, brachytherapy, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 31, 2015 Category: Pharmaceuticals Source Type: news

Theragenics to distribute ART's AccuBoost
Brachytherapy seed manufacturer Theragenics and women's health firm Advanced (more) (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 30, 2015 Category: Radiology Source Type: news

Cianna Medical Raises $8 Million Through Recent Financing Transactions
$4 Million Through GE Capital and $4 Million Through Internal Equity Round ALISO VIEJO, CA--(Healthcare Sales & Marketing Network) - Cianna Medical, Inc., a medical device company dedicated to improving the quality of life for women affected by breast c... Devices, Oncology, Venture CapitalCianna Medical, SAVI SCOUT, SAVI applicator, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 16, 2015 Category: Pharmaceuticals Source Type: news

GE Capital backs Cianna Medical in $8m round
Cianna Medical said today that it raised $8 million for its Savi Scout breast cancer device, including a $4 million debt round from GE Capital and another $4 million equity round from existing backers. Aliso Viejo, Calif.-based Cianna’s Savi Scout is designed to produce audible and visual indicators surgeons can use to tag cancerous tissue during lumpectomy and biopsy procedures. The surgeon uses a hand piece that emits infrared light and electromagnetic waves to locate a reflector placed in target tissue as long as a week before surgery. After reaching the surgical bulls-eye, the surgeon takes out the targ...
Source: Mass Device - July 16, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Surgical Women's Health Breast Cancer Cianna Medical Source Type: news

Varian shows software upgrade at AAPM 2015
Varian Medical Systems has introduced a faster version of its VariSeed brachytherapy (more) (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 15, 2015 Category: Radiology Source Type: news

Breast cancer treatment with fewer potential side effects has equally good patient outcomes, UCLA study shows
A new study by UCLA scientists has found that women diagnosed with breast cancer and treated with a one-week regimen of partial breast radiation after the surgical removal of the tumor, or lumpectomy, saw no increase in cancer recurrence or difference in cosmetic outcomes compared to women who received radiation of the entire breast for a period of up to six weeks after surgery. The study is one of the largest ever done on partial breast irradiation. The study lasted two decades and was led by Dr. Mitchell Kamrava, an assistant professor of radiation oncology at UCLA and member of the Jonsson Comprehensive Cancer Cent...
Source: UCLA Newsroom: Health Sciences - June 26, 2015 Category: Universities & Medical Training Source Type: news

IsoRay faces lawsuits alleging fudged clinical data
IsoRay (NYSE:ISR) is facing putative class-action lawsuits from shareholders accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer. The lawsuits, from at least 3 different shareholders, claim that IsoRay made false statements about a clinical study of Cesium 131. The study was the 1st major peer-reviewed study of the brachytherapy seeds. The Richland, Wash.-based company’s press release came out May 20, 1 day after the study was published in the journal Brachytherapy. IsoRay’s release claimed a ...
Source: Mass Device - June 15, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Clinical Trials Legal News Wall Street Beat IsoRay Source Type: news

My hysterectomy for cancer – Carol’s story
The post My hysterectomy for cancer – Carol’s story appeared first on Hysterectomy Association. In March 2013 I went for my routine annual smear, I have been on yearly smears since the birth of my last daughter in 1997. Two weeks later I received a letter with an appointment to attend the colposcopy clinic which was scheduled for two weeks later (end of April). I attended this and was told I had cin3 pre-cancer cells on my cervix. They tried to do the leep whilst I was there but were unable to do it as the pain was horrendous. So I was advised it needed to be done under a general. The end of May I had my l...
Source: The Hysterectomy Association - June 9, 2015 Category: OBGYN Authors: Linda Tags: Your Stories cancer cervical cancer Source Type: news

Backing Off From Brachytherapy? Deciphering the DeclineBacking Off From Brachytherapy? Deciphering the Decline
The declining use of brachytherapy is an enigma among radiation oncologists. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Brachytherapy Benefits in High-Risk Prostate CancerBrachytherapy Benefits in High-Risk Prostate Cancer
Brachytherapy after external beam radiotherapy (EBRT) doubles the chance of progression-free survival at 9 years when compared with EBRT alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 28, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Combo Brachytherapy Improves Local Control in Cervical CancerCombo Brachytherapy Improves Local Control in Cervical Cancer
A combination of both interstitial and intracavitary brachytherapy for locally advanced cervical cancer improves local control. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Brachytherapy Boosts Survival in Inoperable Endometrial CancerBrachytherapy Boosts Survival in Inoperable Endometrial Cancer
Women with inoperable early-stage endometrial cancer survive longer if their treatment includes brachytherapy rather than external beam radiotherapy alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 27, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Brachytherapy implants boost odds of halting prostate cancer
Prostate cancer patients treated with radioactive implants are twice as likely to find the disease has stabilised after five years, a study has found. (Source: the Mail online | Health)
Source: the Mail online | Health - April 27, 2015 Category: Consumer Health News Source Type: news